These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 28139198)

  • 1. Oxytocin improves behavioral and electrophysiological deficits in a novel Shank3-deficient rat.
    Harony-Nicolas H; Kay M; du Hoffmann J; Klein ME; Bozdagi-Gunal O; Riad M; Daskalakis NP; Sonar S; Castillo PE; Hof PR; Shapiro ML; Baxter MG; Wagner S; Buxbaum JD
    Elife; 2017 Jan; 6():. PubMed ID: 28139198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behavioral Phenotyping of an Improved Mouse Model of Phelan-McDermid Syndrome with a Complete Deletion of the
    Drapeau E; Riad M; Kajiwara Y; Buxbaum JD
    eNeuro; 2018; 5(3):. PubMed ID: 30302388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developmental social communication deficits in the Shank3 rat model of phelan-mcdermid syndrome and autism spectrum disorder.
    Berg EL; Copping NA; Rivera JK; Pride MC; Careaga M; Bauman MD; Berman RF; Lein PJ; Harony-Nicolas H; Buxbaum JD; Ellegood J; Lerch JP; Wöhr M; Silverman JL
    Autism Res; 2018 Apr; 11(4):587-601. PubMed ID: 29377611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled trial of intranasal oxytocin in Phelan-McDermid syndrome.
    Fastman J; Foss-Feig J; Frank Y; Halpern D; Harony-Nicolas H; Layton C; Sandin S; Siper P; Tang L; Trelles P; Zweifach J; Buxbaum JD; Kolevzon A
    Mol Autism; 2021 Sep; 12(1):62. PubMed ID: 34593045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Neurological Manifestations of Phelan-McDermid Syndrome.
    Frank Y
    Pediatr Neurol; 2021 Sep; 122():59-64. PubMed ID: 34325981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autism spectrum disorder in Phelan-McDermid syndrome: initial characterization and genotype-phenotype correlations.
    Oberman LM; Boccuto L; Cascio L; Sarasua S; Kaufmann WE
    Orphanet J Rare Dis; 2015 Aug; 10():105. PubMed ID: 26306707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological enhancement of mGlu5 receptors rescues behavioral deficits in SHANK3 knock-out mice.
    Vicidomini C; Ponzoni L; Lim D; Schmeisser MJ; Reim D; Morello N; Orellana D; Tozzi A; Durante V; Scalmani P; Mantegazza M; Genazzani AA; Giustetto M; Sala M; Calabresi P; Boeckers TM; Sala C; Verpelli C
    Mol Psychiatry; 2017 May; 22(5):689-702. PubMed ID: 27021819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Touchscreen learning deficits and normal social approach behavior in the Shank3B model of Phelan-McDermid Syndrome and autism.
    Copping NA; Berg EL; Foley GM; Schaffler MD; Onaga BL; Buscher N; Silverman JL; Yang M
    Neuroscience; 2017 Mar; 345():155-165. PubMed ID: 27189882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Brazilian cohort of individuals with Phelan-McDermid syndrome: genotype-phenotype correlation and identification of an atypical case.
    Samogy-Costa CI; Varella-Branco E; Monfardini F; Ferraz H; Fock RA; Barbosa RHA; Pessoa ALS; Perez ABA; Lourenço N; Vibranovski M; Krepischi A; Rosenberg C; Passos-Bueno MR
    J Neurodev Disord; 2019 Jul; 11(1):13. PubMed ID: 31319798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered synaptic ultrastructure in the prefrontal cortex of Shank3-deficient rats.
    Jacot-Descombes S; Keshav NU; Dickstein DL; Wicinski B; Janssen WGM; Hiester LL; Sarfo EK; Warda T; Fam MM; Harony-Nicolas H; Buxbaum JD; Hof PR; Varghese M
    Mol Autism; 2020 Nov; 11(1):89. PubMed ID: 33203459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of two Shank3 and the Cacna1c mouse models of autism spectrum disorder.
    Kabitzke PA; Brunner D; He D; Fazio PA; Cox K; Sutphen J; Thiede L; Sabath E; Hanania T; Alexandrov V; Rasmusson R; Spooren W; Ghosh A; Feliciano P; Biemans B; Benedetti M; Clayton AL
    Genes Brain Behav; 2018 Jan; 17(1):4-22. PubMed ID: 28753255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered Behaviors and Impaired Synaptic Function in a Novel Rat Model With a Complete
    Song TJ; Lan XY; Wei MP; Zhai FJ; Boeckers TM; Wang JN; Yuan S; Jin MY; Xie YF; Dang WW; Zhang C; Schön M; Song PW; Qiu MH; Song YY; Han SP; Han JS; Zhang R
    Front Cell Neurosci; 2019; 13():111. PubMed ID: 30971895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased rates of cerebral protein synthesis in Shank3 knockout mice: Implications for a link between synaptic protein deficit and dysregulated protein synthesis in autism spectrum disorder/intellectual disability.
    Torossian A; Saré RM; Loutaev I; Smith CB
    Neurobiol Dis; 2021 Jan; 148():105213. PubMed ID: 33276083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delineation of the genetic and clinical spectrum of Phelan-McDermid syndrome caused by
    De Rubeis S; Siper PM; Durkin A; Weissman J; Muratet F; Halpern D; Trelles MDP; Frank Y; Lozano R; Wang AT; Holder JL; Betancur C; Buxbaum JD; Kolevzon A
    Mol Autism; 2018; 9():31. PubMed ID: 29719671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Definition and clinical variability of SHANK3-related Phelan-McDermid syndrome.
    Schön M; Lapunzina P; Nevado J; Mattina T; Gunnarsson C; Hadzsiev K; Verpelli C; Bourgeron T; Jesse S; van Ravenswaaij-Arts CMA; ; Hennekam RC
    Eur J Med Genet; 2023 Jul; 66(7):104754. PubMed ID: 37003575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 29 Mainland Chinese cohort of patients with Phelan-McDermid syndrome: genotype-phenotype correlations and the role of SHANK3 haploinsufficiency in the important phenotypes.
    Xu N; Lv H; Yang T; Du X; Sun Y; Xiao B; Fan Y; Luo X; Zhan Y; Wang L; Li F; Yu Y
    Orphanet J Rare Dis; 2020 Nov; 15(1):335. PubMed ID: 33256793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phelan-McDermid Syndrome and SHANK3: Implications for Treatment.
    Costales JL; Kolevzon A
    Neurotherapeutics; 2015 Jul; 12(3):620-30. PubMed ID: 25894671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and Genetic Aspects of Phelan-McDermid Syndrome: An Interdisciplinary Approach to Management.
    Cammarata-Scalisi F; Callea M; Martinelli D; Willoughby CE; Tadich AC; Araya Castillo M; Lacruz-Rengel MA; Medina M; Grimaldi P; Bertini E; Nevado J
    Genes (Basel); 2022 Mar; 13(3):. PubMed ID: 35328058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phelan McDermid Syndrome: From Genetic Discoveries to Animal Models and Treatment.
    Harony-Nicolas H; De Rubeis S; Kolevzon A; Buxbaum JD
    J Child Neurol; 2015 Dec; 30(14):1861-70. PubMed ID: 26350728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs prescribed for Phelan-McDermid syndrome differentially impact sensory behaviors in
    Kozol RA; Dallman JE
    F1000Res; 2023; 12():84. PubMed ID: 37868296
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.